King Intensifying CEO Search; Gregory To Immediately Step Down
This article was originally published in The Pink Sheet Daily
Executive Summary
Gregory had planned to retire as CEO once a successor was found. King is facing federal investigations into its Medicaid rebate accounting practices and recently issued an earnings warning.
You may also be interested in...
Newcomer Graceway Acquires 3M’s American Pharmaceutical Business
Headed by former King chief Gregory, the nine-month-old Tennessee pharma gains access to 3M’s immune response modifier platform on which to build a portfolio.
Newcomer Graceway Acquires 3M’s American Pharmaceutical Business
Headed by former King chief Gregory, the nine-month-old Tennessee pharma gains access to 3M’s immune response modifier platform on which to build a portfolio.
Mylan To Pay $4 Bil. For King Ahead Of Launch Of Beta Blocker Nebivolol
The company cites King’s 1,200-person sales force as one reason behind the acquisition. King’s cardiovascular marketing experience with the ACE inhibitor Altace will be beneficial as Mylan anticipates approval for its beta blocker nebivolol.